Insider Selling: United Therapeutics Corp. COO Sells 10,000 Shares of Stock (UTHR)
United Therapeutics Corp. (NASDAQ:UTHR) COO Roger Jeffs unloaded 10,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $110.72, for a total transaction of $1,107,200.00. Following the completion of the sale, the chief operating officer now directly owns 897 shares in the company, valued at approximately $99,316. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Argus raised their price target on shares of United Therapeutics Corp. from $120.00 to $130.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. They noted that the move was a valuation call. Separately, analysts at Jefferies Group raised their price target on shares of United Therapeutics Corp. from $76.00 to $91.00 in a research note to investors on Tuesday, December 24th. They now have a “hold” rating on the stock. Finally, analysts at Ladenburg Thalmann upgraded shares of United Therapeutics Corp. from a “neutral” rating to a “buy” rating in a research note to investors on Monday, December 23rd. They now have a $138.00 price target on the stock. Nine equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $88.21.
United Therapeutics Corp. (NASDAQ:UTHR) traded up 0.37% during mid-day trading on Friday, hitting $111.31. 569,099 shares of the company’s stock traded hands. United Therapeutics Corp. has a 52-week low of $51.38 and a 52-week high of $116.65. The stock has a 50-day moving average of $95.60 and a 200-day moving average of $80.57. The company has a market cap of $5.591 billion and a price-to-earnings ratio of 20.15.
United Therapeutics Corp. (NASDAQ:UTHR) last released its earnings data on Tuesday, October 29th. The company reported $2.98 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.59 by $1.39. The company had revenue of $302.20 million for the quarter, compared to the consensus estimate of $279.02 million. During the same quarter last year, the company posted $2.82 earnings per share. United Therapeutics Corp.’s revenue was up 24.6% compared to the same quarter last year.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.